Ibogaine in Canada: What Health Canada and the Federal Statute Say

Ibogaine Canada searches mostly ask one thing: what is its legal position? In a 2017 notice, Health Canada said ibogaine is not authorized for use in Canada and added it to the Prescription Drug List. In the Controlled Drugs and Substances Act as consolidated in the official sources we read on 31 October 2026, we found no entry for ibogaine in the schedules. Those two facts do not add up to a simple "legal" or "illegal," and the pages we read do not settle what that means for any person or clinic. This page sets out what each official text says, which access pathways Health Canada describes, and what we could not confirm. It is general information, not legal advice, and it does not say whether any clinic or program in Canada is legal.

Ibogaine on the Prescription Drug List

On 19 May 2017 Health Canada published a notice adding ibogaine and its salts, derivatives or analogues to the Human and Veterinary Prescription Drug Lists, effective at the time of posting. The notice says ibogaine is not authorized for use in Canada. It gives as reasons that Health Canada had received serious and fatal adverse reaction reports linked to ibogaine, and that in June 2015 it had issued a risk communication advising the public not to use it.

The notice describes what listing was expected to do: allow sale only on a prescription, restrict the compounding of products containing ibogaine, and give enforcement agents more authority to seize products that do not conform to the Food and Drugs Act and Regulations. The notice does not mention the Controlled Drugs and Substances Act. It is a 2017 document, and we did not check for later changes to the list.

The Controlled Drugs and Substances Act

The consolidated text of the Controlled Drugs and Substances Act on the Department of Justice site is marked current to 30 September 2026 and last amended on 18 July 2026. Its Schedule III names substances such as LSD, DMT, psilocin and psilocybin. We downloaded the page and searched its full text for "ibogaine," "iboga" and "Tabernanthe," and found no match, including in the schedules.

That is a finding about what we read, not a legal conclusion. The search looked for those spellings only, and a reader should confirm it on the Justice site. What the absence means for a particular person is a question for a Canadian lawyer, not for this page. The Act works together with regulations, and the Justice site's Controlled Substances Regulations say in section 239 that they come into force on 1 October 2026, a date that had passed on the day we read it. We did not read the rest of those regulations.

Pathways Health Canada describes

The Special Access Program. Health Canada's Special Access Program page says a health or dental practitioner can request a drug that is unavailable for sale in Canada. The practitioner must be entitled under provincial or territorial law to treat patients with an unapproved drug and have prescribing privileges there. The request must be for a medical emergency, which Health Canada interprets as a serious or life-threatening condition where conventional treatments have failed, are unsuitable or are unavailable in Canada. The page says timelines vary case by case. It does not name ibogaine, and we found no source showing that a request involving ibogaine has been authorized.

Psychedelic-assisted therapy requests. A Health Canada notice of 27 February 2023 says the psychedelic drugs most often used in psychedelic-assisted psychotherapy are psilocybin and MDMA and that both are restricted drugs. It does not mention ibogaine. The related class exemption, effective 5 January 2022, covered activities with psilocybin and MDMA authorized through the Special Access Program, and it names no other substance. Health Canada's page, last updated on 17 December 2025, says the exemption would be revoked when the new Controlled Substances Regulations take effect on 1 October 2026. Because those regulations' own text gives the same date, which has passed, the exemption was due to be revoked then. We did not confirm the revocation or what replaced the exemption.

Section 56 exemptions. Section 56(1) of the Controlled Drugs and Substances Act lets the Minister of Health, on any terms the Minister considers necessary, exempt a person, a class of persons or a controlled substance from provisions of the Act or its regulations. The Minister must consider the exemption necessary for a medical or scientific purpose or otherwise in the public interest. Health Canada's list of class exemptions, dated 24 September 2026, does not mention ibogaine. We did not find an individual exemption for ibogaine in any source we read.

Clinical trials

We did not find an official Health Canada record of an ibogaine clinical trial. We did not search any trial registry, including Health Canada's Clinical Trials Database and ClinicalTrials.gov, so this is a limit of our reading and not a statement that no trial exists.

Legal position is not a safety signal

A 2026 review in the journal Addiction describes a rare but clinically significant risk of prolonged QTc interval and potentially fatal ventricular arrhythmias with ibogaine, reports that these events have occurred at therapeutic doses and in people without known heart conditions, and says treatment should take place only under controlled medical supervision with rigorous cardiovascular monitoring. Health Canada's 2017 notice also cites serious and fatal adverse reaction reports. Neither says that any setting is safe.

How this page was made

We read each source named here on 31 October 2026. The Controlled Drugs and Substances Act page was downloaded and searched as text, and several Health Canada and Justice pages were read through an automated summarizing tool, so the wording above is our paraphrase. We did not contact any clinic, agency or lawyer, and we list no clinics. Rules and notices change, so check current official sources before relying on this page. If you have a health question about ibogaine or about stopping a substance, talk with a qualified physician.